Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 3/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 14/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | DDX3X | O00571 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5522106 | 0.92 | PTGES (0.49) | PTGESALOX5 | |
| SCHEMBL2698878 | 0.88 | HDAC11 (0.48) | LCKEGFRSRCZAP70PTGES | |
| SCHEMBL13393208 | 0.83 | PTGES (0.48) | PTGESHDAC11ALOX5 | |
| SCHEMBL2701451 | 0.82 | PTGES (0.45) | PTGESHDAC11ALOX5 | |
| SCHEMBL1964691 | 0.81 | POLB (0.45) | LCKEGFRSRCZAP70PTGES | |
| SCHEMBL1969553 | 0.81 | LCK (0.46) | LCKEGFRSRCZAP70PTGES | |
| SCHEMBL13393002 | 0.80 | PTGES (0.44) | PTGESHDAC11 | |
| SCHEMBL1964863 | 0.79 | HDAC11 (0.47) | LCKEGFRSRCZAP70PTGES | |
| SCHEMBL1968284 | 0.78 | HDAC11 (0.52) | LCKEGFRSRCZAP70PTGES | |
| SCHEMBL16318318 | 0.78 | HDAC11 (0.52) | LCKEGFRSRCZAP70PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519149-B2 | Tricyclic compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-27 | — | — | US | disclosed |
| US-20120108583-A1 | Tricyclic Compounds As mPGES-1 Inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108583-A1 | Tricyclic Compounds As mPGES-1 Inhibitors | PTGES, PTGS1, PTGIS | LCK 3046/4885EGFR 3292/4885SRC 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.